Silexion Therapeutics
SLXNSilexion Therapeutics is a clinical-stage biotechnology company focused on developing RNA interference (RNAi) therapies for cancers driven by KRAS mutations.
Table of contents
Earnings
Next report
Aug 11, 2026 (In 1 week)Competitors
By market cap
By revenue growth
Profile
Silexion Therapeutics is a clinical-stage biotechnology company focused on developing RNA interference (RNAi) therapies for cancers driven by KRAS mutations. The company's proprietary platform silences the KRAS oncogene to prevent the production of oncogenic proteins, rather than inhibiting the proteins after they are formed. Their lead candidate, SIL204, is being developed as an integrated treatment for non-resectable locally advanced pancreatic cancer.
Silexion is a clinical-stage developer utilizing a differentiated siRNA approach to target the root cause of KRAS mutations, positioning itself against traditional small-molecule protein inhibitors.
Questions, answered.
- What is Silexion Therapeutics's market cap?
- Silexion Therapeutics (SLXN) has a market capitalization of $2.7M and trades on XNAS.
- Who are Silexion Therapeutics's competitors?
- Silexion Therapeutics's key competitors include Amgen, Bristol-Myers Squibb, Revolution Medicines, and others. These companies compete in similar markets and product categories.
- Who does Silexion Therapeutics partner with?
- Silexion Therapeutics's notable partners include H.C. Wainwright & Co., White Lion Capital, LLC, Israeli Innovation Authority.
- What subsidiaries does Silexion Therapeutics have?
- Silexion Therapeutics's subsidiaries include Silexion Therapeutics Ltd., Moringa Acquisition Corp.
- Where is Silexion Therapeutics headquartered?
- Silexion Therapeutics is headquartered in Israel. It has been publicly traded since 2024.